Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pathophysiology in rickets/osteomalacia].

Yasuhiro Takeuchi1

  • 1Toranomon Hospital Endocrine Center.

Clinical Calcium
|October 2, 2007
PubMed
Summary
This summary is machine-generated.

Rickets and osteomalacia cause bone fragility due to impaired vitamin D action or hypophosphatemia. Fibroblast growth factor (FGF) 23 dysregulation is a key factor in phosphate metabolism and disease development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eldecalcitol and calcium supplementation in Chinese women with postmenopausal osteoporosis: a prospective observational cohort study.

Journal of bone and mineral metabolism·2026
Same author

Unexpected [18F]-fluciclovine hyperuptake in radiation necrosis after proton therapy: illustrative case.

Journal of neurosurgery. Case lessons·2026
Same author

Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 2-Year Results from the Phase 3 PaTHway-Trial.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Impact of physical and chemical parameters on spinoculation for chimeric antigen receptor T cell manufacturing using a quality-by-design approach.

Molecular therapy. Advances·2026
Same author

A carotid web with accumulation of myofibroblasts: a case report.

BMC neurology·2026
Same author

Palopegteriparatide in Japanese adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway Japan trial.

Endocrine journal·2025
Same journal

[The frontier of adipocyte biology, cold environment induces thermogenic genes via epigenomic switch.]

Clinical calcium·2019
Same journal

[Sequential treatment of osteoporosis with anti-sclerostin.]

Clinical calcium·2019
Same journal

[The sequential therapy of romosozumab followed by denosumab for osteoporosis.]

Clinical calcium·2019
Same journal

[Wnt signaling in myeloma.]

Clinical calcium·2019
Same journal

[Fate decision of hematopoietic stem cells by Wnt signaling.]

Clinical calcium·2019
Same journal

[Control of inflammatory bone destruction by targeting the Wnt signaling pathway.]

Clinical calcium·2019
See all related articles

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Mineral Homeostasis

Background:

  • Rickets/osteomalacia involves mineralization defects and skeletal fragility, affecting children and adults.
  • Bone matrix protein production and architecture remain intact.
  • Pathophysiology stems from impaired vitamin D actions or hypophosphatemia.

Purpose of the Study:

  • To review the pathophysiology of rickets and osteomalacia.
  • To highlight the roles of vitamin D and fibroblast growth factor (FGF) 23.
  • To emphasize FGF23's significance in phosphate metabolism.

Main Methods:

  • Literature review of rickets/osteomalacia.
  • Analysis of vitamin D metabolism and action.
  • Examination of hypophosphatemia causes, focusing on FGF23 and renal tubular dysfunction.

Related Experiment Videos

Main Results:

  • Impaired vitamin D action results from deficiency, impaired activation, or vitamin D receptor dysfunction.
  • Hypophosphatemia is commonly caused by excessive FGF23 activity or renal tubular dysfunction.
  • FGF23 is identified as a principal regulator of phosphate metabolism.

Conclusions:

  • Rickets/osteomalacia pathogenesis is linked to vitamin D deficiency or hypophosphatemia.
  • Fibroblast growth factor (FGF) 23 plays a critical role in phosphate regulation and disease.
  • Further research into FGF23's physiological and pathophysiological roles is ongoing.